艾曲波帕在血小板减少中的应用进展

Application progress of eltrombopag in thrombocytopenia

血小板减少是临床中常见的疾病,严重者可危及生命。血小板生成素受体激动剂(TPO-RA)可有效提高血小板减少患者的血小板计数,减少输血依赖。目前,第2代TPO-RA艾曲波帕已被批准用于慢性免疫性血小板减少症(cITP)、重型再生障碍性贫血(SAA)及慢性丙型肝炎病毒(HCV)感染等疾病相关血小板减少。笔者拟就艾曲波帕在血小板减少中的应用进展进行综述。

Thrombocytopenia is a common disease in the clinic. In severe cases, it can be life-threatening. Thrombopoietin receptor agonists (TPO-RA) can effectively increase platelet counts in patients with thrombocytopenia and reduce blood transfusion dependence. As the second-generation TPO-RA, eltrombopag (EP) has been approved for thrombocytopenia caused by chronic immune thrombocytopenic purpura (cITP), severe aplastic anemia(SAA), and infection of chronic hepatitis C (HCV). This article reviews the progress of the application of EP in thrombocytopenia.